盐酸缬更昔洛韦片的治疗效果怎么样呢？

The tablet is an antiviral drug produced by the Swiss company Roche. It is used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients. Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

What is the therapeutic effect of Valganciclovir Hydrochloride Tablets?

The safety and efficacy of Valganciclovir treatment were verified in two different trials: The antiviral effect of Valganciclovir was clinically confirmed by the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with Valganciclovir, and the U.S. Food and Drug Administration (FDA) approved the increased use of Valganciclovir in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with valganciclovir hydrochloride tablets (Valganciclovir) reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients treated for 100 days) to 16.8% (for patients treated for 200 days) one year after receiving a kidney transplant (p <0.0001).1.2 The overall safety profile of Valganciclovir does not change when prophylaxis is extended in high-risk renal transplant patients.